Joel Lusman insider trades: Autoimmune (AIMM) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Joel reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 30, 2009 | AIMM | ↑ Buy | 78,300 | $1.22 | $96K | Indirect | Jun 30, 2009 (0d) |
| Feb 3, 2009 | AIMM | ↑ Buy | 118,000 | $0.90 | $106K | Indirect | Feb 3, 2009 (0d) |
| Oct 8, 2008 | AIMM | ↑ Buy | 61,100 | $1.32 | $81K | Indirect | Oct 8, 2008 (0d) |
| Oct 2, 2008 | AIMM | ↑ Buy | 86,500 | $1.36 | $118K | Indirect | Oct 3, 2008 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Joel Lusman's insider trades
Joel Lusman is a 10% owner of Autoimmune (AIMM). Since Oct 2, 2008, Joel has reported 4 open-market purchases worth $400K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AIMM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.